Early-Stage drug combo study for MDS halted
NCT ID NCT04810611
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 30 times
Summary
This study tested combinations of drugs in 33 adults with lower-risk myelodysplastic syndrome (MDS), a blood disorder. The goal was to find safe doses and understand side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City Of Hope National Med Center Oncology
Duarte, California, 91010, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
MD Anderson Cancer Center/University of Texas MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital .
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Prahran, Victoria, 3181, Australia
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Salamanca, Castille and León, 37007, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
The Ohio State University Wexner Medical Center .
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.